2021-01-11,Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
2021-01-04,Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-22,Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
2020-12-18,Is KNSA A Good Stock To Buy Now?
2020-12-15,Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
2020-11-30,Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
2020-11-24,Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
2020-11-23,Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
2020-11-17,Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020
2020-11-16,Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
2020-11-10,Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
2020-11-09,Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
2020-11-05,Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
2020-10-29,Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress
2020-10-26,Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
2020-10-14,"Hedge Funds Are Starting To Get Bullish On Kiniksa Pharmaceuticals, Ltd. (KNSA)"
2020-10-07,"Company News for Oct 7, 2020"
2020-10-06,Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
2020-09-24,"Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th"
2020-09-21,Kiniksa Announces Upcoming Rilonacept Analyst Day
2020-09-15,Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
2020-09-09,Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-08-31,Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
2020-08-04,Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
2020-07-30,Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
2020-07-28,"Do Insiders Own Lots Of Shares In Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?"
2020-07-21,"Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering"
2020-07-20,"Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering"
2020-07-16,Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
2020-07-08,J.P. Morgan Says These 3 Stocks Will Surge Over 30% From Current Levels
2020-07-05,"Hedge Funds Are Betting On Kiniksa Pharmaceuticals, Ltd. (KNSA)"
2020-06-30,"Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group"
2020-06-30,"Company News for Jun 30, 2020"
2020-06-29,3 Strong Buy Coronavirus Stocks With Massive Upside Potential
2020-06-29,Kiniksa Reports Positive Results of Pericarditis-Drug Trial
2020-06-29,5 Stocks With Recent Price Strength Amid Spike in Coronavirus
2020-06-29,Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
2020-06-17,Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
2020-06-12,"Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group"
2020-06-10,Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
2020-06-08,Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
2020-06-04,Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
2020-05-29,Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020
2020-05-22,How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry
2020-05-18,"Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares"
2020-05-13,"Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering"
2020-05-13,"Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering"
2020-05-11,Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
2020-05-06,Will Kiniksa Pharmaceuticals Continue to Surge Higher?
2020-04-28,Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
2020-04-22,Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
2020-04-08,Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?
2020-04-06,Coronavirus Stocks Gain: Vir Biotech up 26.6%; Kiniksa off 0.7%
2020-04-06,3 Healthcare Stocks Fighting the Coronavirus
2020-04-01,"Company News for Apr 1, 2020"
2020-03-31,Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
2020-03-30,Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
2020-02-26,Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
2020-02-11,Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
2020-02-05,"Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat"
2020-01-13,Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
2019-12-19,"The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals"
2019-12-18,"Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More"
2019-12-16,"Did Hedge Funds Drop The Ball On Kiniksa Pharmaceuticals, Ltd. (KNSA) ?"
2019-12-12,"Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy"
2019-12-11,"Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector"
2019-12-11,Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of YescartaÂ® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
2019-12-10,Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
2019-12-07,We're Keeping An Eye On Kiniksa Pharmaceuticals's (NASDAQ:KNSA) Cash Burn Rate
2019-11-21,"Company News For Nov 21, 2019"
2019-11-20,Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
2019-11-20,Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
2019-11-16,Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
2019-11-12,Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
2019-11-01,"Were Hedge Funds Right About Selling Kiniksa Pharmaceuticals, Ltd. (KNSA)?"
2019-10-28,Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
2019-10-08,Kiniksa Pharmaceuticals Enters Oversold Territory
2019-09-19,Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research
2019-08-19,Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
2019-08-12,Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
2019-08-12,Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial
2019-08-06,Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference
2019-08-05,Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community
2019-06-29,"Is Kiniksa Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?"
2019-06-12,Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology
2019-06-10,The Kiniksa Pharmaceuticals (NASDAQ:KNSA) Share Price Is Down 23% So Some Shareholders Are Getting Worried
2019-05-30,Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019
2019-05-29,Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
2019-05-16,Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research
2019-05-13,Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
2019-05-02,Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
2019-04-29,"Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ?"
2019-04-23,"Long-Term ""GameChangers"" in Biotech"
2019-04-17,Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology
2019-04-08,Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs
2019-03-18,Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiologys 68th Annual Scientific Session
2019-03-07,Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity
2019-02-28,Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
2019-02-26,Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference
2019-01-31,"Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering"
